Literature DB >> 6160352

The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.

J A Dominic, D W Bourne, T G Tan, E B Kirsten, R G McAllister.   

Abstract

The pharmacokinetics of verapamil were determined in 8 normal male subjects (age range, 24-28 years) after administration of 0.2 mg/kg over a 3-4 min period. Plasma drug concentrations were measured by a gas-chromatographic method using a nitrogen-specific detector with a sensitivity of 5 ng/ml. Verapamil levels fell in a biexponential pattern, and the data were fitted to a two-compartment model with the NONLIN computer program. The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min. The P-R interval of the surface electrocardiogram was increased in each subject in direct proportion to the verapamil plasma level, but with considerable between-subject variability. One subject developed transient Mobitz I block at a plasma drug concentration of 162 ng/ml. At peak verapamil concentrations, mean T-wave amplitude decreased 35 +/- 11% from control height. The results of this study suggest that P-R interval prolongation can be used as an indication of verapamil effect in patients with sinus rhythm.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6160352     DOI: 10.1097/00005344-198101000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

3.  Modulation of mitomycin C-induced multidrug resistance in vitro.

Authors:  R T Dorr; J D Liddil
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Pharmacokinetics of verapamil in patients with renal failure.

Authors:  J Mooy; M Schols; M v Baak; M v Hooff; A Muytjens; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

6.  Endovascular treatment of medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  P Jun; N U Ko; J D English; C F Dowd; V V Halbach; R T Higashida; M T Lawton; S W Hetts
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

Authors:  R Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; G P Trevi; M Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.